Manufacturing, Gene Therapies

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.

The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.

CBER maps modernization plan to handle surge in research and applications.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.

For cell and gene therapies to reach their full potential, changes in manufacturing must be explored.

Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.

Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.

Eli Lilly and Company plans to build two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

VectorBuilder will expand with the construction of new $500 million Gene Delivery Research and Manufacturing Campus in Guangzhou, China.

UCB has announced it will build a new innovative gene therapy facility in Belgium.

CGTs offer hope for the future of treatments, but the costly manufacturing, slow turnaround time, and need for supplies hinder progress.

Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.

Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.